Ovarian Angiogenesis

The Ovary: Second Edition

Volumn , Issue , 2004, Pages 305-317

  Geva, Eli ^a   Jaffe, Robert B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942782424     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012444562-8/50019-7     Document Type: Chapter

References (92)

1. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
2. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
3. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 23:442-447.
4. Risau W. Mechanism of angiogenesis. Nature 1997, 386:671-674.
5. Gordon J.D., Shifren J.L., Foulk R.A., Taylor R.N., Jaffe R.B. Angiogenesis in the human female reproductive tract. Obstet. Gynecol. Surv. 1995, 50:688-697.
6. Shay-Salit A., Shushy M., Wolfovitz E., Yahav H., Breviario F., Dejana E., Resnick N. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc. Natl. Acad. Sci. USA 2002, 99:9462-9467.
7. Reynolds L.P., Killilea S.D., Redmer D.A. Angiogenesis in the female reproductive system. FASEB J. 1992, 6:886-892.
8. Findlay J.K. Angiogenesis in reproductive tissues. J. Endocr. 1986, 111:357-366.
9. Augustin H.G., Braun K., Telemenakis I., Modlich U., Kuhn W. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am. J. Pathol. 1995, 147:339-351.
10. Goede V., Schmidt T., Kimmina S., Kozian D., Augustin H.G. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab. Invest. 1998, 78:1385-1394.
11. Greenwald G.S. Temporal and topographic changes in DNA synthesis after induced follicular atresia. Biol. Reprod. 1989, 41:175-178.
12. Dharmarajan A.M., Bruce N.W., Meyer G.T. Quantitative ultrastructural characteristics relating to transport between luteal cell cytoplasm and blood in the corpus luteum of the pregnant rat. Am. J. Anat. 1985, 172:87-99.
13. Reynolds L.P. Utero-ovarian interactions during early pregnancy: Role of conceptus-induced vasodilation. J. Anim. Sci. 1986, 62:47-61.
14. Jones G.S., Maffezzoli R.D., Strott C.A., Ross G.T., Kaplan G. Pathophysiology of reproductive failure after clomiphene-induced ovulation. Am. J. Obstet. Gynecol. 1970, 108:847-867.
15. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 1992, 267:26031-26037.
16. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 1993, 4:1317-1326.
17. Geva E., Jaffe R.B. The role of vascular endothelial growth factor (VEGF) in ovarian physiology and pathology. Fertil. Steril. 2000, 74:429-438.
18. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
19. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 1992, 189:824-831.
20. Nicosia R.F., Nicosia S.V., Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am. J. Pathol. 1994, 145:1023-1029.
21. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992, 114:521-532.
22. Shifren J.L., Doldi N., Ferrara N., Mesiano S., Jaffe R.B. In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: Implications for mode of action. J. Clin. Endocrinol. Metab. 1994, 79:316-322.
23. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
24. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277:48-50.
25. Jain R.K., Munn L.L. Leaky vessels? Call Ang-1!. Nat. Med. 2000, 6:131-132.
26. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
27. Roberts W.G., Palade G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell. Sci. 1995, 108:2369-2379.
28. Dellian M., Witwer B.P., Salehi H.A., Yuan F., Jain R.K. Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am. J. Pathol. 1996, 149:59-71.
29. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
30. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
31. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 1998, 95:9349-9354.
32. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
33. Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. Biologic implications of expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 1998, 83:2528-2533.
34. Kamat B.R., Brown L.F., Manseau E.J., Senger D.R., Dvorak H.F. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am. J. Pathol. 1995, 46:157-165.
35. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
36. Geva, E., Byrne, A., Zaloudek, C., and Jaffe, R. B., unpublished.
37. Hazzard T.M., Molskness T.A., Chaffin C.L., Stouffer R.L. Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the periovulatory interval. Mol. Hum. Reprod. 1999, 5:1115-1121.
38. Gordon J.D., Mesiano S., Zaloudek C.J., Jaffe R.B. Vascular endothelial growth factor localization in human ovary and fallopian tubes: Possible role in reproductive function and ovarian cyst formation. J. Clin. Endocrinol. Metab. 1996, 81:353-359.
39. Otani N., Minami S., Yamoto M., Shikone T., Otani H., Nishiyama R., Otani T., Nakano R. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J. Clin. Endocrinol. Metab. 1999, 84:3845-3851.
40. Yamamoto S., Konishi I., Tsuruta Y., Nanbu K., Mandai M., Kuroda H., Matsushita K., Hamid A.A., Yura Y., Mori T. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol. Endocrinol. 1997, 11:371-381.
41. Zeleznik A.J., Schuler H.M., Reichert L.J. Gonadotropin-binding sites in the rhesus monkey ovary: Role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology 1981, 109:356-362.
42. Jakeman L.B., Winer J., Bennett G.L., Altar C.A., Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. 1992, 89:244-253.
43. Ferrara N., Chen H., Davis-Smyth T., Gerber H.P., Nguyen T.N., Peers D., Chisholm V., Hillan K.J., Schwall R.H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 1998, 4:336-340.
44. Laitinen M., Ristimaki A., Honkasalo M., Narko K., Paavonen K., Ritvos O. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinology 1997, 138:4748-4756.
45. Mueller M.D., Jean-Louis V., Minchenko A., Lebovic D.I., Leitman D.C., Taylor R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors α and β. Proc. Natl. Acad. Sci. USA 2000, 97:10972-10977.
46. Palter S.F., Tavares A.B., Hourvitz A., Veldhuis J.D., Adashi E.Y. Are estrogens of import to primate/human ovarian folliculogenesis?. Endocr. Rev. 2001, 22:389-424.
47. Hyder S.M., Murthy L., Stancel G.M. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 1998, 58:392-395.
48. Sone H., Okuda Y., Kawakami Y., Kondo S., Hanatani M., Matsuo K., Suzuki H., Yamashita K. Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture. Life Sci. 1996, 59:21-25.
49. Friedman C.I., Danforth D.R., Herbosa-Encarnacion C., Arbogast L., Alak B.M., Seifer D.B. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Fertil. Steril. 1997, 68:607-612.
50. Agrawal R., Conway G., Sladkevicius P., Tan S.L., Engmann L., Payne N., Bekir J., Campbell S., Jacobs H. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: Relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil. Steril. 1998, 70:651-658.
51. Agrawal R., Sladkevicius P., Engmann L., Conway G.S., Payne N.N., Bekis J., Tan S.L., Campbell S., Jacobs H.S. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum. Reprod. 1998, 13:651-655.
52. Adams J., Franks S., Polson D.W., Mason H.D., Abdulwahid N., Tucker M., Morris D.V., Price J., Jacobs H.S. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985, 2:1375-1379.
53. Balen A. In vitro fertilization and the patient with polycystic ovaries. Polycystic Ovary Syndrome 2000, 159-182. Cambridge University Press, Cambridge, England. 1st ed.
54. Folkman J., Ingber D.E. Angiostatic steroids. Method of discovery and mechanism of action. Ann. Surg. 1987, 206:374-383.
55. Neulen J., Yan Z., Raczek S., Weindel K., Keck C., Weich H.A., Marme D., Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab. 1995, 80:1967-1971.
56. Whelan J.G., Vlahos N.F. The ovarian hyperstimulation syndrome. Fertil. Steril. 2000, 73:883-896.
57. Krasnow J.S., Berga S.L., Guzick D.S., Zeleznik A.J., Yeo K.T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report. Fertil. Steril. 1996, 65:552-555.
58. D'Ambrogio G., Fasciani A., Monti M., Cattani R., Genazzani A.R., Artini P.G. Serum vascular endothelial growth factor levels before starting gonadotropin treatment in women who have developed moderate forms of ovarian hyperstimulation syndrome. Gynecol. Endocrinol. 1999, 13:311-315.
59. Abramov Y., Barak V., Nisman B., Schenker J.G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil. Steril. 1997, 67:261-265.
60. Ludwig M., Bauer O., Lopens A., Jelkmann W., Diedrich K. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. Hum. Reprod. 1998, 13:30-32.
61. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.V., Connolly D.T., Robertson D.M. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994, 344:235-236.
62. Levin E.R., Rosen G.F., Cassidenti D.L., Yee B., Meldrum D., Wisot A., Pedram A. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J. Clin. Invest. 1998, 102:1978-1985.
63. Ravindranath N., Little-Ihrig L., Phillips H.S., Ferrara N., Zeleznik A.J. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 1992, 131:254-260.
64. Neulen J., Yan Z., Raczek S., Weindel K., Keck C., Weich H.A., Marme D., Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab. 1995, 80:1967-1971.
65. Perez R.P., Godwin A.K., Hamilton T.C., Ozols R.F. Ovarian cancer biology. Semin. Oncol. 1991, 18:186-204.
66. Olson T.A., Mohanraj D., Carson L.F., Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994, 54:276-280.
67. Viglietto G., Romano A., Maglione D., Rambaldi M., Paoletti I., Lago C.T., Califano D., Monaco C., Mineo A., Santelli G., Manzo G., Botti G., Chiappetta G., Persico M.G. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placentaderived growth factor. Oncogene 1996, 13:577-587.
68. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Senger D.R., Dvorak H.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993, 53:4727-4735.
69. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular permeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97-132.
70. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992, 3:65-71.
71. Popovici R.M., Irwin J.C., Giaccia A.J., Giudice L.C. Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: Potential relevance to menstruation and endometrial regeneration. J. Clin. Endocrinol. Metab. 1999, 84:2245-2248.
72. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. 1996, 271:29483-29488.
73. Hu Y.L., Tee M.K., Goetzl E.J., Auersperg N., Mills G.B., Ferrara N., Jaffe R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 2001, 93:762-768.
74. Kieser A., Weich H.A., Brandner G., Marme D., Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9:963-969.
75. Grugel S., Finkenzeller G., Weindel K., Barleon B., Marme D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 1995, 270:25915-25919.
76. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 1996, 56:2299-2301.
77. Byrne A.T., Geva E., Zaloudek C., Yanacopoulos G., Jaffe R.B. Angiogenesis and cancer: From basic mechanisms to therapeutic applications. Expression and Quantitation of Angiopoietin-1 and -2 mRNA in the Normal Postmenopausal Ovary and Progressive Stages Leading to Ovarian Carcinoma. Proceedings, Amer. Assn. Cancer Res. 2001, 42:721. Abstract in.
78. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 1999, 153:1249-1255.
79. Hu L., Hofmann J., Zaloudek C., Ferrera N., Hamilton T., Jaffe R.B. VEGF immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 2002, 161:1917-1924.
80. Hu L., Zaloudek C., Mills G.B., Gray J., Jaffe R.B. In vivo and in vitro carcinoma growth inhibition by PI3 kinase inhibitor (LY294002). Clin. Cancer Res. 2000, 6:880-886.
81. Hu L., Hofmann J., Lu Y., Mills G.B., Jaffe R.B. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002, 62:1087-1092.
82. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., Ryan T.E., Bruno J., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 27:1161-1169.
83. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
84. Geva E., Jaffe R.B. Role of angiopoietins in reproductive tract angiogenesis. Obstet. Gynecol. Surv. 2000, 55:511-519.
85. Asahara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., Yancopoulos G.D., Isner J.M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 1998, 83:233-240.
86. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc. Natl. Acad. Sci. USA 2002, 99:11205-11210.
87. Wulff C., Wilson H., Largue P., Duncan W.C., Armstrong D.G., Fraser H.M. Angiogenesis in the human corpus luteum: Localization and changes in angiopoietins, tie-2, and vascular endothelial growth factor messenger riboucleic acid. J. Clin. Endocrinol. Metab. 2000, 85:4302-4309.
88. Bryne A.T., Geva E., Zaloudek C., Yancoupolos G., Jaffe R.B. Expression and Quantitation of Angiopoietin-1 and -2 mRNA in the Normal Postmenopausal Ovary and Progressive Stages Leading to Ovarian Carcinoma. Proceeding, Amer. Assn. Cancer Res. 2001, 42:3872. Abstract in.
89. LeCouter J., Lin R., Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organispecific regulation of angiogenesis. Nat. Med. 2002, 8:913-917.
90. Fraser H.M., Dickson S.E., Lunn S.F., Wulff C., Morris K.D., Carroll V.A., Bicknell R. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 2000, 141:995-1000.
91. Wulff C., Wilson H., Rudge J.S., Wiegand S.J., Lunn S.F., Fraser H.M. Luteal angiogenesis: Prevention and intervention by treatment with vascular endothelial growth factor trap (A40). J. Clin. Endocrinol. Metab. 2001, 86:3377-3386.
92. Wulff C., Wilson H., Wiegand S.J., Rudge J.S., Fraser H.M. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 2002, 143.